You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.
Last week, Invitae launched its Non-Invasive Prenatal Screening test while Myriad expanded its Prequel Prenatal Screen to cover all aneuploidies.
The company will compete by continuing product improvements, ramping up marketing presence, and launching an app to improve doctor and consumer engagement.
The firm reported total revenu 16.8 million, up from $187.9 million in Q2 2018 and just above analysts' average estimate.
The article argues that PRS are bad at identifying those who will develop disease but others say this is the same for widely used risk factors.
CMS's move to restrict coverage could limit test access for early-stage cancer patients and negatively impact lab revenues.
Among the firms presenting, 10x noted that it doubled its revenue growth in 2018, and Myriad discussed the impact that new tests are having on its growth.
Data from the GUIDED study will be central to commercial payor discussions, a Medicare LCD reconsideration request, and eventually expansion into the primary care market.
The investment bank upgraded the company's stock to an Outperform rating from Market Perform but lowered its price target to $37 per share.
Co-founder and former CEO of Myriad Genetics, Peter Meldrum, has died, the Wall Street Journal reports.
A tissue sample from the 1960s harbors a near-complete sample of HIV, IFLScience reports.
A new bill would reshape the US National Science Foundation to include a focus on technological development, according to Science.
The Food and Drug Administration's decision to halt a SARS-CoV-2 study has drawn criticism, according to Stat News.
In Genome Biology this week: features affecting gut microbiome and parasite patterns, cellular interactions in lung tumor microenvironment, and more.